Chin J Cancer Res: Phase III study by Prof. Baohui Han's team shows that QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer

Recently, the Chinese Journal of Cancer Research published a 2-year follow-up update of a study by Professor Han Baohui's team from Shanghai Chest Hospital, which mainly evaluated the comparison of bevacizumab biosimilar QL1101 with bevacizumab in the treatment of non-patients.
Efficacy and safety in squamous non-small cell lung cancer .

Recently, the Chinese Journal of Cancer Research published a 2-year follow-up update of a study by Professor Han Baohui's team from Shanghai Chest Hospital, which mainly evaluated the comparison of bevacizumab biosimilar QL1101 with bevacizumab in the treatment of non-patients.

Efficacy and safety in squamous non-small cell lung cancer .

The study is a multicenter, randomized, double-blind, parallel, phase III clinical trial (NCT03169335)
.

A total of 535 eligible patients with NSCLC were included in this randomized controlled trial

The study is a multicenter, randomized, double-blind, parallel, phase III clinical trial (NCT03169335)

Median DOR (187 days vs 212 days, HR (90% CI), 1.

After exclusion of related confounding factors, the overall ORR was 53.
1% in the QL1101 arm and 54.
3% in the bevacizumab arm (QL1101 vs bevacizumab: relative risk = 0.
977; 90% CI: 0.
838-1.
144)
.

The median PFS in the QL1101 group and the bevacizumab group was 235 days and 254 days, respectively (logrank P=0.

After exclusion of related confounding factors, the overall ORR was 53.

The mean shrinkage ratio of targeted lesions was also similar in the QL1101 and bevacizumab groups (22.
5% vs.
23.
5%)
.

The mean shrinkage ratio of targeted lesions was also similar in the QL1101 and bevacizumab groups (22.
5% vs.
23.
5%)
.

The mean shrinkage ratio of targeted lesions was also similar in the QL1101 and bevacizumab groups (22.

For patients receiving maintenance therapy, there were similar outcomes between the QL1101 group (n=157) and the bevacizumab group (n=148) (PFS: 253 days vs.
272 ​​days, log-rank P=0.
387; OS : 673 days vs 790 days, log-rank P=0.
101; mean tumor shrinkage: 26.
6% vs.
27.
5%)
.

For patients receiving maintenance therapy, there were similar outcomes between the QL1101 group (n=157) and the bevacizumab group (n=148) (PFS: 253 days vs.
272 ​​days, log-rank P=0.
387; OS : 673 days vs 790 days, log-rank P=0.
101; mean tumor shrinkage: 26.
6% vs.
27.
5%)
.

For patients receiving maintenance therapy, there were similar outcomes between the QL1101 group (n=157) and the bevacizumab group (n=148) (PFS: 253 days vs.

In terms of adverse drug reactions, among the 157 patients using QL1101, 65 had grade 1 adverse reactions, 57 had grade 2 adverse reactions, and 15 had grade 3 adverse reactions
.

Among the 148 bevacizumab patients, 37 had grade 1 adverse reactions, 24 had grade 2 adverse reactions, and 16 had grade 3 adverse reactions

In terms of adverse drug reactions, among the 157 patients using QL1101, 65 had grade 1 adverse reactions, 57 had grade 2 adverse reactions, and 15 had grade 3 adverse reactions

In conclusion, the study shows that the bevacizumab biosimilar QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
.

In conclusion, the study shows that the bevacizumab biosimilar QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
.
Studies have shown that the bevacizumab biosimilar QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
.
Studies have shown that the bevacizumab biosimilar QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
.

 

Original source:

Original source:

Jun Lu, Tianqing Chu, Hongyu Liu, Minjuan Hu, Yuqing Lou, Yanwei Zhang, Zhiqiang Gao, Wei Zhang, Xueyan Zhang, Huimin Wang, Hua Zhong, Baohui Han.
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous nonsmall cell lung cancer patients : A two-year follow-up data update.
Chin J Cancer Res, 2022; 34(1), 28-39.
doi: 10.
21147/j.
issn.
1000-9604.
2022.
01.
03

Jun Lu, Tianqing Chu, Hongyu Liu, Minjuan Hu, Yuqing Lou, Yanwei Zhang, Zhiqiang Gao, Wei Zhang, Xueyan Zhang, Huimin Wang, Hua Zhong, Baohui Han.
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous nonsmall cell lung cancer patients : A two-year follow-up data update.
Chin J Cancer Res, 2022; 34(1), 28-39.
doi: 10.
21147/j.
issn.
1000-9604.
2022.
01.
03 Jun Lu, Tianqing Chu, Hongyu Liu, Minjuan Hu, Yuqing Lou, Yanwei Zhang, Zhiqiang Gao, Wei Zhang, Xueyan Zhang, Huimin Wang, Hua Zhong, Baohui Han.
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous nonsmall cell lung cancer patients: A two-year follow-up data update .
Chin J Cancer Res, 2022; 34(1), 28-39.
doi: 10.
21147/j.
issn.
1000-9604.
2022.
01.
03 Leave a comment here